Publications by authors named "Hasnita Hassan"
Article Synopsis
- This study examined bleeding outcomes after thrombolytic therapy in STEMI patients at a Malaysian hospital from 2016 to 2020.
- Out of 941 patients, 16.6% experienced bleeding, with major and minor bleeding linked to higher in-hospital mortality rates.
- Age and Malaysian Chinese ethnicity were associated with higher bleeding risk, while being a foreigner and smoking were linked to lower risk; gastrointestinal bleeding was notably more common in patients treated with streptokinase.
Article Synopsis
- This study analyzed the incidence and outcomes of failed thrombolysis (FT) in STEMI patients who received pharmacological reperfusion in a public hospital over a four-year period.
- Out of 941 patients, 10.3% experienced in-hospital mortality, with FT occurring in 9.1% of cases, significantly increasing the risk of death.
- Key predictors of FT included age, pre-existing health conditions (like hypertension and stroke), and elevated heart rates at presentation, which can help in early risk assessment for better patient management.
Introduction: Some guidelines had recommended "thrombolysis first" in ST-elevated myocardial infarction (STEMI) during the Coronavirus Disease 2019 (COVID-19) outbreak. The impact of COVID-19 solely on STEMI thrombolysis is lacking as most studies reported outcomes related to percutaneous coronary intervention (PCI) setting. Thus, this study aimed to assess the impact of the COVID-19 pandemic on STEMI thrombolysis outcomes and the Emergency Department's performance in a non-PCI capable centre.
View Article and Find Full Text PDFBackground: Fibrinolysis remains the primary reperfusion strategy for ST-elevation myocardial infarction (STEMI) in many Asian countries. The outcomes and factors affecting mortality in STEMI fibrinolysis in the Asian population are lacking despite being widely used.
Objectives: This study aimed to assess the clinical profile of patients and predictors affecting STEMI mortality in an Asian population.
The outcomes of reperfusion therapy with streptokinase versus tenecteplase in ST-elevation myocardial infarction (STEMI): a propensity-matched retrospective analysis in an Asian population.
Int J Clin Pharm
June 2022
Background Fibrinolysis using streptokinase or tenecteplase remains the primary reperfusion strategy for ST-elevation myocardial infarction (STEMI) in many Asian countries, including Malaysia. Comparative outcomes of these two fibrinolytic agents in the Asian population were inconclusive despite being widely used. Aim We aimed to assess and compare the outcomes of streptokinase versus tenecteplase in STEMI reperfusion of an Asian population.
View Article and Find Full Text PDF